Staar Surg Stock Price, News & Analysis

Alcon (SIX/NYSE: ALC) and STAAR Surgical (NASDAQ: STAA) agreed to adjourn STAAR’s Special Meeting of Stockholders originally scheduled for October 23, 2025 in connection with STAAR’s merger agreement with Alcon. The Special Meeting is adjourned until 8:30 a.m. Pacific Time on November 6, 2025. No other business will be conducted at the Special Meeting. The record date for stockholders eligible to vote remains the close of business on September 12, 2025. Stockholders with voting questions are directed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at toll-free +1 877-750-8233 or banks/brokers +1 212-750-5833.

Yunqi Capital (NASDAQ:STAA), a 5.1% STAAR shareholder, urged the board to hold the special shareholder meeting on October 23, 2025 and reiterated its opposition to the proposed sale to Alcon. Yunqi criticized STAAR’s pre-merger process and called recent company disclosures “disingenuous.”

Yunqi highlighted preliminary Q3 results: China revenue YTD $142.6M, estimated Q3 China revenue ≈$54.4M, $25.6M consignment revenue, and said Q3 sales exceeded consensus by 2.8%. Yunqi projects China sales of $180–200M for 2026 versus STAAR’s $160M guide and flagged missing margin/profit detail before the vote.

STAAR Surgical (NASDAQ: STAA) reported preliminary Q3 2025 net sales of $94.7 million, a 6.9% increase versus $88.6 million a year earlier. Results included $25.9 million recognized in Q3 from a December 2024 ICL shipment to a China distributor that received extended payment terms.

Excluding that collection, the company saw 7.7% growth outside China while China distributors reduced purchases, lowering nine-month sales as they trimmed inventory by approximately $80–$85 million. Figures are unaudited and subject to final 10-Q review. A special stockholder meeting on Oct 23, 2025 will vote on the Alcon merger proposal.

Broadwood Partners (NASDAQ: STAA), which holds 27.5% of STAAR outstanding shares, sent a letter to STAAR Surgical’s board on October 17, 2025 urging directors to allow a timely shareholder vote on the proposed sale to Alcon (NYSE: ALC). Broadwood urges shareholders to vote AGAINST the acquisition announced August 5, 2025, arguing the board pursued a poorly designed process and an inadequate price.

Broadwood warns the board against delaying the October 23, 2025 vote or issuing misleading statements, and says shareholders and proxy advisors oppose the deal; it calls for the board to accept the vote result and work with shareholders if the transaction is rejected.